摘要
目的研究舒利迭治疗咳嗽变异性哮喘的临床效果及对患者诱导痰中炎性介质的影响。方法将咳嗽变异性哮喘患者86例,随机分成对照组和观察组各43例。对照组采用氨茶碱、酮芬治疗,观察组在对照组治疗基础上加用舒利迭治疗。比较两组患者在第一秒用力呼气容积(FEV1)、用力肺活量(FVC)、呼气高峰流量(PEFR)水平上的差异以及治疗的总有效率。结果观察组患者总有效率为95.35%,高于对照组患者总有效率76.74%,差异具有统计学意义(P<0.05)。治疗后,观察组患者日间咳嗽积分、夜间咳嗽积分低于对照组患者日间咳嗽积分、夜间咳嗽积分,差异具有统计学意义(P<0.05)。治疗4、7、10、12个月后,观察组患者白细胞介素-5(IL-5)、外周血嗜酸性粒细胞(EOS)水平均低于对照组,观察组患者IL-10水平高于对照组,差异均具有统计学意义(P<0.05)。治疗后,观察组患者FEV1、FVC、PEFR水平高于对照组,差异具有统计学意义(P<0.05)。结论舒利迭可有效提高咳嗽变异性哮喘患者的临床治疗效果、改善炎性介质和提高患者生活质量。
Objective To research clinical effects of seretide on cough variant asthma （CVA） and inflammatory mediators of sputum of patients. Methods 86 patients with CVA were randomly divided into control group and observa- tion group. The control group was treated with aminophylline and Ketotifen. The observation was treated with seretide and the treatment of the control group. The total effective rate, FEV1, FVC, PEFR level of the patients of the two groups were compared. Result The total effective rate of the observation group （95.35%） was higher than that in the control group （76.74%）. The difference was statistically significant （P〈0.05）. After treatment, daytime cough and night cough integration in the observation group were lower than in that the control group （P〈0.05）. After 4.7.10.12 months treatment, IL-5 and EOS levels in the observation group lower than that in the control group, while IL-10 levels in the observation group was higher than that in the control group. The difference was statistically significant （P〈0.05）. After treatment, FEV1, FVC and PEFR levels in the observation group were higher than that in the control group. The differences were statistically significant （P〈0.05）. Conclusion Seretid treats CVA can significantly im- prove the therapeutic effect, inflammatory mediators and the quality of life of patients.
出处
《西部医学》
2016年第1期84-86,共3页
Medical Journal of West China
基金
四川省卫生厅重点科研课题(201228283)
作者简介
通讯作者：杨俊勇，E-mail：xiyangjunyong@sina．com
